Hepatitis C virus window-phase infections: Closing the window on hepatitis C virus

Transfusion

Volumn 48, Issue 4, 2008, Pages 594-600

  Tuke, Philip W ^a   Grant, Paul R ^a   Waite, James ^a   Kitchen, Alan D ^a   Eglin, Roger P ^a   Tedder, Richard S ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ARTICLE; CONTROLLED STUDY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MEDICAL INSTRUMENTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS LOAD;

ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS, VIRAL, HUMAN; HUMANS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 41149084205     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01584.x     Document Type: Article

References (24)

1. World Health Organization. Wkly Epidemiol Rec 1997 72 : 65 72.
2. Trepo C, Pradat P. Hepatitis C virus infection in Western Europe. J Hepatol 1999 31 : 80 3.
3. Department of Health. Hepatitis C. Action plan for England. Dept Health Rep 2004 40180.
4. Hutchinson SJ, Roy KM, Wadd S, Bird SM, Taylor A, Anderson E, Shaw L, Codere G, Goldberg DJ. Hepatitis C virus infection in Scotland: epidemiological review and public health challenges. Scott Med J 2006 51 : 8 15.
5. Soldan K, Davison K, Dow B. Estimates of the frequency of HBV, HCV and HIV infectious donations entering the blood supply in the United Kingdom, 1996-2003. Euro Surveill 2005 10 : 17 9.
6. Glynn SA, Wright DJ, Kleinman SH, Hirschkorn D, Tu Y, Heldebrant C, Smith R, Giachetti C, Gallarda J, Busch MP. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005 45 : 994 1002.
7. Barrera JM, Francis B, Ercilla G, Nelles M, Achord D, Darner J, Lee SR. Improved detection of anti-HCV in posttransfusion hepatitis by a third-generation ELISA. Vox Sang 1995 68 : 15 8.
8. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005 45 : 254 64.
9. Pillonel J, Laperche S. Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro Surveill 2005 10 : 5 8.
10. Velati C, Fomiatti L, Baruffi L, Romano L, Zanetti A. Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001-2003). Euro Surveill 2005 10 : 12 4.
11. Grant PR, Sims CM, Tedder RS. Quantification of HCV RNA levels and detection of core antigen in donations before seroconversion. Transfusion 2002 42 : 1032 6.
12. Xie L, Wu XD, Huang DZ, Chen HL, He LX, Wang J, Han DK. Clinical application and analysis of hepatitis C virus NS3 antigen detection by ELISA in human serum. Chin Med J (Engl) 2007 120 : 294 9.
13. Shang G, Seed CR, Wang F, Nie D, Farrugia A. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004. Transfusion 2007 47 : 529 39.
14. Fabrizi F, Lunghi G, Aucella F, Mangano S, Barbisoni F, Bisegna S, Vigilante D, Limido A, Martin P. Novel assay using total hepatitis C virus (HCV) core antigen quantification for diagnosis of HCV infection in dialysis patients. J Clin Microbiol 2005 43 : 414 20.
15. Takahashi M, Saito H, Higashimoto M, Atsukawa K, Ishii H. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J Clin Microbiol 2005 43 : 186 91.
16. Courouce AM, Le Marrec N, Bouchardeau F, Razer A, Maniez M, Laperche S, Simon N. Efficacy of HCV core antigen detection during the preseroconversion period. Transfusion 2000 40 : 1198 202.
17. Laperche S, Elghouzzi MH, Morel P, Asso-Bonnet M, Le Marrec N, Girault A, Servant-Delmas A, Bouchardeau F, Deschaseaux M, Piquet Y. Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing? Transfusion 2005 45 : 1965 72.
18. Schnuriger A, Dominguez S, Valantin MA, Tubiana R, Duvivier C, Ghosn J, Simon A, Katlama C, Thibault V. Early detection of hepatitis C virus infection by use of a new combined antigen-antibody detection assay: potential use for high-risk individuals. J Clin Microbiol 2006 44 : 1561 3.
19. Jarvis LM, Dow BC, Cleland A, Davidson F, Lycett C, Morris K, Webb B, Jordan A, Petrik J. Detection of HCV and HIV-1 antibody negative infections in Scottish and Northern Ireland blood donations by nucleic acid amplification testing. Vox Sang 2005 89 : 128 34.
20. Harris KA, Gilham C, Mortimer PP, Teo CG. The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. J Med Virol 1999 58 : 127 31.
21. Harris HE, Eldridge KP, Harbour S, Alexander G, Teo CG, Ramsay ME. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? J Viral Hepat 2007 14 : 213 20.
22. Buckton AJ, Ngui SL, Arnold C, Boast K, Kovacs J, Klapper PE, Patel B, Lbrahim I, Rangarajan S, Ramsay ME, Teo CG. Multitypic hepatitis C virus infection identified by real-time nucleotide sequencing of minority genotypes. J Clin Microbiol 2006 44 : 2779 84.
23. Mohsen AH. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001 48 : 707 13.
24. Burton J. A and others vs. National Blood Authority. Queen's Bench Division. ALL ER(D) 2001 Mar : 298.